

10/825,758

STN- Structure Searched
1.27.05

=> d ibib abs hitstr 1-24

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:688277 CAPLUS

DOCUMENT NUMBER: 140:59822

TITLE: Preparation of (5 α ,13 α)-D-azasteroids as key precursors of a new family of potential GABAA receptor modulators

AUTHOR(S): Wang, Cunde; Wang, Shaozhong; Xu, Yingju; Hu, Yuefei; Hu, Hongwen

CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China

SOURCE: Steroids (2003), 68(7-8), 677-683

CODEN: STEDAM; ISSN: 0039-128X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:59822

AB Three groups of (5 α ,13 α)D-azasteroids, (5 α ,13 α)-3-hydroxy-17 α -aza-D-homoandrostans, (5 α ,13 α)-3-hydroxy-17-aza-D-homoandrostans, and (5 α ,13 α)-3-hydroxy-17-azaandrostans, were designed and synthesized as key precursors for the further preparation of a new family of potential GABAA receptor modulators from com. available natural steroids (5 α)-3-hydroxyandrostane-17-ones.

IT 639461-78-2P 639461-85-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (5 α ,13 α)-D-azasteroids from (5 α)-3-hydroxyandrostane-17-ones)

RN 639461-78-2 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 8-(acetyloxy)tetradecahydro-10 α ,12 α -dimethyl-, (4aS,4bR,6aS,8R,10aS,10bS,12aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 639461-85-1 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 8-(acetyloxy)tetradecahydro-10 α ,12 α -dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

On ventos
 L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:319919 CAPLUS
 DOCUMENT NUMBER: 138:338333
 TITLE: Preparation of sulfamoyl steroidal imide derivs. for inhibition of steroid sulfatase
 INVENTOR(S): Potter, Barry Victor Lloyd; Reed, Michael John; Woo, Lok Wai Lawrence
 PATENT ASSIGNEE(S): Sterix Limited, UK
 SOURCE: PCT Int. Appl., 156 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033518	A1	20030424	WO 2002-GB4686	20021017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002032409	A2	20020425	WO 2001-GB4645	20011018
WO 2002032409	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1448592	A1	20040825	EP 2002-801418	20021017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005014776	A1	20050120	US 2004-825758	20040416
PRIORITY APPLN. INFO.:			GB 2001-25073	A 20011018
			WO 2001-GB4645	A 20011018



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:311321 CAPLUS

DOCUMENT NUMBER: 139:271191

TITLE: Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity

AUTHOR(S): Fischer, Delphine S.; Chander, Surinder K.; Woo, L. W. Lawrence; Fenton, Janine C.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.

CORPORATE SOURCE: Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK

SOURCE: Journal of Steroid Biochemistry and Molecular Biology (2003), 84(2-3), 343-349

CODEN: JSBBEZ; ISSN: 0960-0760

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In pursuit of novel steroid sulfatase (STS) inhibitors devoid of estrogenicity, several D-ring modified steroid derivs. were synthesized. In vitro evaluation of the compds. identified two highly potent inhibitors, 4a and 4b, which were 18 times more active than estrone-3-O-sulfamate (EMATE), both having IC50 values of .apprx.1 nM. These 16,17-seco-estra-1,3,5(10)-triene-16,17-imide derivs. were synthesized from estrone, via the intermediate 1, which was easily alkylated, deprotected and sulfamoylated affording the final compds. in high yields. To assess their biol. profile, the selected inhibitors were tested for their in vivo inhibitory potency and estrogenicity in ovariectomized rats. After an oral dose of 10 mg/kg per day for 5 days, 4a and 4b were found to inhibit rat liver steroid sulfatase by 99%. They were also devoid of estrogenic activity in the uterine weight gain assay, indicating that these two leads have therapeutic potential for the treatment of hormone-dependent breast cancer.

IT 415974-72-0P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(novel D-ring modified steroid derivs. as potent, non-estrogenic, steroid sulfatase inhibitors with rat in-vivo activity)


RN 415974-72-0 CAPLUS

CN Sulfamic acid, (4aS,4bR,10bS,12aS)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydro-12a-methyl-1,3-dioxo-2-propylnaphth[2,1-f]isoquinolin-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/825,758

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:235023 CAPLUS
DOCUMENT NUMBER: 139:85532
TITLE: D-Ring Modified Estrone Derivatives as Novel Potent Inhibitors of Steroid Sulfatase
AUTHOR(S): Fischer, Delphine S.; Woo, L. W. Lawrence; Mahon, Mary F.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.
CORPORATE SOURCE: Department of Pharmacy and Pharmacology and Sterix Ltd., Medicinal Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(8), 1685-1700
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:85532
GI



I

AB A series of novel D-ring modified derivs. of estrone was synthesized and tested as inhibitors of steroid sulfatase (STS). The steroidal D-ring was cleaved via an iodoform reaction and thermal condensation of the resulting marrianolic acid derivative gave 16,17-seco-estra-1,3,5(10)-triene-16,17-imide derivs., where a piperidinedione moiety is in place of the D-ring. This synthetic approach was found to give a higher overall yield than the literature method of Beckmann rearrangement. A range of alkyl side chains have been introduced on the nitrogen atom of the imido-ring and the corresponding 3-O-sulfamates synthesized. The new D-ring modified estrone derivs. bearing a Pr (I) and a pyridin-3-ylmethyl moiety had IC50 values of 1 nM when tested in placental microsomes for the inhibition of STS. These compds. are therefore up to 18-fold more potent than EMATE, the very first highly potent irreversible steroidal STS inhibitor.


10/825,758



RN 556050-42-1 CAPLUS

CN Sulfamic acid, (4aS,4bR,10bS,12aS)-2-(4-chlorobutyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydro-12a-methyl-1,3-dioxonaphth[2,1-f]isoquinolin-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:314755 CAPLUS

DOCUMENT NUMBER: 136:340868

TITLE: Preparation of estrone derivatives for therapeutic use as steroid sulfatase and steroid dehydrogenase inhibitors for treatment of breast cancer

INVENTOR(S): Potter, Barry Victor Lloyd; Reed, Michael John

PATENT ASSIGNEE(S): Sterix Limited, UK

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032409	A2	20020425	WO 2001-GB4645	20011018
WO 2002032409	A3	20020808		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002010687	A5	20020429	AU 2002-10687	20011018
WO 2003033518	A1	20030424	WO 2002-GB4686	20021017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1448592	A1	20040825	EP 2002-801418	20021017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005014776	A1	20050120	US 2004-825758	20040416
PRIORITY APPLN. INFO.:				
			GB 2000-25788	A 20001020
			GB 2001-25073	A 20011018
			WO 2001-GB4645	W 20011018
			GB 2002-9274	A 20020423
			WO 2002-GB4686	W 20021017


OTHER SOURCE(S): MARPAT 136:340868
GI



AB Estrone derived. sulfamoyloxy-azasteroids, such as I [R = H, OMe; R1 = H, alkyl, alkenyl, benzyl, picolyl, etc.], were prepared for pharmaceutical use as steroid sulfatase and steroid dehydrogenase inhibitors for treatment of diseases involving estrogen biosynthesis, such as breast cancer. Thus, I (R = H, R1 = CH₂Ph) was prepared via a series of synthetic steps which included conversion of 3-O-benzylestrone to dicarboxylic acid II using I₂ and KOH in MeOH, cyclocondensation of II with PhCH₂NH₂ by heating at 180° for 3 h, hydroxyl deprotection of the N,O-dibenzylazaestratriene by Pd/C catalyzed hydrogenation, and reaction of the N-benzyl-3-hydroxyazaestratriene with sulfamoyl chloride in DMA. The prepared sulfamoyloxy-azasteroids were assayed for their effect on conversion of estrone to estradiol in T47D and MDA-MB-231 breast cancer cells and for modulation of steroid sulfatase activity using MCF-7 human breast cancer cells. Pharmaceutical formulations of the azasteroids were also discussed.

IT 415974-69-5P 415974-70-8P 415974-71-9P
415974-72-0P 415974-73-1P 415974-74-2P
415974-75-3P 415974-76-4P 415974-77-5P


10/825,758



RN 415974-83-3 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4a,4b,5,6,10b,11,12,12a-octahydro-9-methoxy-12a-methyl-8-(phenylmethoxy)-, (4aS,4bR,10bS,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 415974-84-4 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4a,4b,5,6,10b,11,12,12a-octahydro-8-hydroxy-9-methoxy-12a-methyl-, (4aS,4bR,10bS,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:467634 CAPLUS

DOCUMENT NUMBER: 135:257385


TITLE: Synthesis of (5 α)-17-azaandrostan-3-ols and (5 α)-17-aza-D-homoandrostan-3-ols and their N-acylated derivatives

AUTHOR(S): Jiang, X.; Wang, J.; Hu, J.; Ge, Z.; Hu, Y.; Hu, H.; Covey, D. F.


CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China

10/825,758

SOURCE: Steroids (2001), 66(8), 655-662
CODEN: STEDAM; ISSN: 0039-128X
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:257385
GI



I



II

AB Two groups of N-acylated D-azasteroids I and II (R = Ac, COCF₃, COCH₂OH) were synthesized to explore structure-activity relationships for steroid modulation of GABAA receptor function. The target compds. were prepared conveniently from (5 α)-3-hydroxyandrostane-17-ones via the intermediate (5 α)-17-aza-D-homoandrostane-3-ols II (R = H) or (5 α)-17-azaandrostane-3-ols I (R = H) precursors in high overall yields. A Beckmann rearrangement and a Hofmann rearrangement were employed as two key steps in the synthetic sequences.


IT 35570-06-0P 35574-26-6P 85639-97-0P
361434-75-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of (5 α)-17-azaandrostane-3-ols and (5 α)-17-aza-D-homoandrostane-3-ols and N-acylated derivs.)

RN 35570-06-0 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-hydroxy-10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35574-26-6 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 8-(acetyloxy)tetradecahydro-10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/825,758



RN 85639-97-0 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-hydroxy-10a,12a-dimethyl-, (4aS,4bR,6aS,8R,10aS,10bS,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361434-75-5 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 8-(acetyloxy)tetradecahydro-10a,12a-dimethyl-, (4aS,4bR,6aS,8R,10aS,10bS,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:784759 CAPLUS

DOCUMENT NUMBER: 134:101057


TITLE: Tigogenine-based synthesis of 3 β -hydroxy- and 3 α -methoxy-17-aza-D-homoandrostanes

AUTHOR(S): Amiranashvili, L.; Menshova, N.; Suvorov, N.

CORPORATE SOURCE: Georgian Academy of Sciences, I. Kutateladze Inst. of

10/825,758

SOURCE: Pharmacochimistry, Georgia
Bulletin of the Georgian Academy of Sciences (2000),
161(2), 252-253
CODEN: BGASFC; ISSN: 1560-0262
PUBLISHER: Georgian Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB On the basis of local vegetable raw material - tigogenin - the new derivs. of D-homo-androstane line - 3 β -hydroxy- (I; R = H) and 3 α -methoxy-17-aza-D-homoandrostanes (I; R = Me) have been synthesized with an aim to study influence of the D-ring transformation on the anti-arrhythmic activity, as compared to 5 α -androstane line derivs.


IT 35574-26-6P, 3 β -Acetoxy-17-aza-D-homoandrostane-16,17a-dione
131325-52-5P, 3 α -Methoxy-17-aza-D-homoandrostane-16,17a-dione

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tigogenin-based synthesis of 3 β -hydroxy- and 3 α -methoxy-17-aza-D-homoandrostanes)

RN 35574-26-6 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 8-(acetyloxy)tetradecahydro-10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131325-52-5 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-methoxy-10a,12a-dimethyl-, (4aS,4bR,6aS,8R,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:533593 CAPLUS
 DOCUMENT NUMBER: 131:351525
 TITLE: Synthesis and biological activity of some D-ring modified estrone derivatives
 AUTHOR(S): Gupta, Ranju; Jindal, Dharam Paul; Borrás, M.; Legros, N.; Leclercq, G.
 CORPORATE SOURCE: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(5), 563-571
 CODEN: IJSBDB; ISSN: 0376-4699
 PUBLISHER: National Institute of Science Communication, CSIR
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:351525
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB 3-Methoxy-17-aza-D-homo-1,3,5(10)-estratriene-16,17a-dione [I; R = MeO, R1 = H], 16,17a-dioxo-17-aza-D-homo-1,3,5(10)-estratrien-3-yl acetate [I; R = OAc, R1 = H] and a series of related compds. have been synthesized from 3-methoxy-16-oximino-1,3,5(10)-estratrien-17-one [II; R = MeO] and 3-hydroxy-16-oximino-1,3,5(10)-estratrien-17-one [II; R = H], resp. The compds. I [R, R1 = MeO, H (DPJ-280); OH, Bu (DPJ-369); OH, allyl (DPJ-370); OH, CH2CH2NMe2 (DPJ-354); OH, 2-pyrrolidinoethyl (DPJ-320); OH, NH2 (DPJ-321); OH, H (DPJ-374)] and DPJ-284 have been evaluated for their estrogenic/antiestrogenic activities and the compds. I [R = MeO throughout, R1 = H, CH2CH2NMe2, CH2CH2NEt2, 2-pyrrolidinoethyl, 2-piperidinoethyl, Me, Bu, allyl] and I [R, R1 = OAc, H; 2-pyrrolidinoethoxy, butyl; OAc, allyl; OH, CH2CH2NMe2; OH, 2-piperidinoethyl; OH, NH2; butoxy, butyl] and III have been screened for antineoplastic activity at NCI, Bethesda.

IT 35570-05-9P 250636-96-5P 250636-98-7P
 250636-99-8P 250637-00-4P 250637-01-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and biol. activity of D-ring modified estrone derivs.)
 RN 35570-05-9 CAPLUS



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1995:589259 CAPLUS
 DOCUMENT NUMBER: 123:112502
 TITLE: Synthesis and biological activity of steroidal imides
 AUTHOR(S): Verma, A. K.; Jindal, D. P.
 CORPORATE SOURCE: Department Pharmaceutical Sciences, Panjab University, Chandigarh, 160 014, India
 SOURCE: European Journal of Medicinal Chemistry (1995), 30(4), 339-41
 CODEN: EJMCA5; ISSN: 0223-5234
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I

AB Azahomosteroids I [R = OH, R1 = H; R = H, R1 = Me] were prepared from I [R = R1 = H]. I are devoid of aromatase-inhibiting and antineoplastic activity.
 IT **158661-63-3**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (synthesis and biol. activity of steroidal imides)
 RN 158661-63-3 CAPLUS
 CN 17-Aza-D-homoandrost-4-ene-3,16,17a-trione (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/825,758




IT 165618-28-0P 165618-30-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of steroidal imides)

RN 165618-28-0 CAPLUS

CN 17-Aza-D-homoandrosta-4-ene-3,16,17a-trione, 17-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165618-30-4 CAPLUS

CN 17-Aza-D-homoandrosta-4-ene-3,16,17a-trione, 4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1994:656112 CAPLUS

DOCUMENT NUMBER: 121:256112

TITLE: Synthesis and biological activity of 17-azasteroidal neuromuscular-blocking agents

10/825,758

AUTHOR(S): Verma, A. K.; Lee, C. Y.; Habtemariam, S.; Harvey, A. L.; Jindal, D. P.
CORPORATE SOURCE: Department of Pharmaceutical Sciences, Panjab University, Chandigarh, 160 014, India
SOURCE: European Journal of Medicinal Chemistry (1994), 29(5), 331-8
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB New analogs of chandonium iodide have been prepared and evaluated for potential neuromuscular blocking activity in in vitro studies using chick biventer cervicis prepns. All the biquaternary compds. I [R = R¹, R² = Me, Et, Bu; X = I, Br, Cl] showed potent neuromuscular-blocking activity but slightly less than chandonium iodide. There is a slight increase in the interonium distance between the 2 quaternary heads of I [R = R¹, R² = Me, X = I]. Monoquaternary ammonium derivs. I [R = N-methylpyrrolidinium, R² = H, X = I; R = OH, OAc, R² = Me, X = I] and II were also synthesized and pharmacol. tested. They exhibited weak neuromuscular-blocking activity as compared to the biquaternary compds. and chandonium iodide.

IT 158661-63-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of azahomoandrostenes)

RN 158661-63-3 CAPLUS

CN 17-Aza-D-homoandrost-4-ene-3,16,17a-trione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/825,758

L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:43281 CAPLUS

DOCUMENT NUMBER: 114:43281

TITLE: Steroids. LV. Synthesis of 16 β -amino-3 β ,17 β -dihydroxy-5 α -androstane from epiandrosterone and the structure of its triacetate

AUTHOR(S): Amiranashvili, L. Sh.; Sladkov, V. I.; Lindeman, S. V.; Aleksanyan, M. S.; Struchkov, Yu. T.; Suvorov, N. N.

CORPORATE SOURCE: Mosk. Khim.-Tekhnol. Inst., Moscow, USSR

SOURCE: Zhurnal Organicheskoi Khimii (1990), 26(5), 1052-8


CODEN: ZORKAE; ISSN: 0514-7492

DOCUMENT TYPE: Journal

LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 114:43281

GI



AB The title compound I was prepared in 2 steps from epiandrosterone via oxime II.


IT 35574-26-6P 131325-52-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 35574-26-6 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 8-(acetyloxy)tetradecahydro-10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131325-52-5 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-methoxy-10a,12a-dimethyl-, (4aS,4bR,6aS,8R,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1989:633353 CAPLUS
 DOCUMENT NUMBER: 111:233353
 TITLE: Photoinduced molecular transformations. 104.
 Pathways of the photorearrangements of five-membered
 cyclic steroidal α -nitro ketones to N-hydroxy
 cyclic imides, cyclic hydroxamic acid, and cyclic
 imide
 AUTHOR(S): Suginome, Hiroshi; Kurokawa, Yoshitaka
 CORPORATE SOURCE: Fac. Eng., Hokkaido Univ., Sapporo, 060, Japan
 SOURCE: Journal of Organic Chemistry (1989), 54(25), 5945-53
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 111:233353
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The photolysis of 5- and 7-membered cyclic steroidal α -nitro ketones was studied. The photolysis of 16-nitroandrostane-17-one I, which exists largely in the enol form in EtOH, gave cyclic N-hydroxy imide II as the major product. II was formed via a photochem. rearrangement. The photolysis of 15 α -nitro-5 α -androstane-16-one III, which exists exclusively in the keto form in EtOH, gave cyclic imide IV. The photolysis of 7-membered cyclic α -nitro ketones V and VI gave the corresponding α -hydroxyimino ketones.


IT 123239-89-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 123239-89-4 CAPLUS

CN 17-Aza-D-homoandrostane-16,17a-dione, 17-hydroxy-, (5 α)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1983:198550 CAPLUS
 DOCUMENT NUMBER: 98:198550
 TITLE: Steroids. III. New synthesis of ring-D seco steroids
 AUTHOR(S): Takahashi, Tomoyoshi; Satoh, Yasuo
 CORPORATE SOURCE: Sch. Med., Jikei Univ., Tokyo, 182, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1983),
 56(1), 355-6
 CODEN: BCSJA8; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Azidoandrostanones I ($R = \alpha\text{-HO}, \beta\text{-HO}$) were cleaved with $\text{Br}_2\text{-HOAc}$ at room temperature, to androstanoic acids II ($R = \alpha\text{-AcO}, \beta\text{-AcO}; R_1 = \text{cyano}, \text{CONH}_2$). Aza-D-homoandrostandiones III were also prepared
 IT 35570-06-0P 85639-97-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 35570-06-0 CAPLUS
 CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-hydroxy-10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/825,758




RN 85639-97-0 CAPLUS
CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-hydroxy-10a,12a-dimethyl-, (4aS,4bR,6aS,8R,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1981:109816 CAPLUS
DOCUMENT NUMBER: 94:109816
TITLE: Separation of some estrogens by thin-layer chromatography
AUTHOR(S): Petrovic, Slobodan M.; Traljic, Eva; Petrovic, Julijana A.
CORPORATE SOURCE: Fac. Technol., Univ. Novi Sad, Novi Sad, 21000, Yugoslavia
SOURCE: Journal of Chromatography (1981), 205(1), 223-6
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Solns. of 13 estrogens (0.5% solns. in CHCl₃) were spotted on silica gel-coated glass plates and developed by 2-dimensional ascending chromatog. using 8:1 C₆H₆:Me₂CO, 7:1 C₆H₆:EtOAc, 4:1 CHCl₃:EtOAc, 2:1 hexane:Me₂CO, or 8:1 cyclohexane:Me₂CO. Optimum sepsns. were achieved by using 8:1 C₆H₆:Me₂CO or 8:1 cyclohexane:Me₂CO.
IT 35570-05-9
RL: PRP (Properties)
(thin-layer chromatog. in separation of)
RN 35570-05-9 CAPLUS
CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4a,4b,5,6,10b,11,12,12a-octahydro-8-methoxy-12a-methyl-, (4aS,4bR,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1974:478133 CAPLUS
 DOCUMENT NUMBER: 81:78133
 TITLE: Acyloin condensation of the trimethyl ester of
 dl-9β-marrianolic acid
 AUTHOR(S): Andryushina, V. A.; Popova, E. V.; Anisimova, O. S.;
 Grinenko, G. S.
 CORPORATE SOURCE: Vses. Nauchno-Issled. Khim.-Farm. Inst.im.
 Ordzhonikidze, Moscow, USSR
 SOURCE: Zhurnal Organicheskoi Khimii (1974), 10(6), 1212-15
 CODEN: ZORKAE; ISSN: 0514-7492
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB Marrianolate I was treated with Na in NH₃(1)-Et₂O to give 57%
 oxahomoestratriene II, 21% estratrienediol III, and 10% azahomoestratriene
 IV.
 IT **53187-59-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 53187-59-0 CAPLUS
 CN 17-Aza-D-homoestra-1,3,5(10)-triene-16,17a-dione, 3-methoxy-,
 (9β)-(±)-(9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1974:121184 CAPLUS
 DOCUMENT NUMBER: 80:121184
 TITLE: Rearrangements of steroids. VII. Schmidt reaction
 and Beckmann rearrangement of estrone and its
 derivatives
 AUTHOR(S): Matkovics, Bela; Tarodi, Bela; Belaspiri, Lajos
 CORPORATE SOURCE: Inst. Anim. Physiol., Attila Jozsef Univ., Szeged,
 Hung.
 SOURCE: Acta Chimica Academiae Scientiarum Hungaricae (1974),

10/825,758

80(1), 79-87

CODEN: ACASA2; ISSN: 0001-5407

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB The products of the Schmidt reaction of estrones I (R = H, Me, cyclopentyl, Ac) and Beckman rearrangement of estrone oximes II (R = H, Me, cyclopentyl, Ac) were determined. E.g., II (R = H) was heated in pyridine containing 4-AcNHC₆H₄SO₂Cl to give 17a-aza-D-homoestratriene III (R = H) and secoestratetraene IV (R = H); I (R = H) was heated in polyphosphoric acid with NaN₃ to give III (R = H) and 17-aza-D-homoestratriene V (R = H).


IT 52075-48-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 52075-48-6 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4a,4b,5,6,10b,11,12,12a-octahydro-8-hydroxy-12a-methyl-, (4aS,4bR,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:405672 CAPLUS

DOCUMENT NUMBER: 77:5672

TITLE: D-Homoimide derivatives of steroids

INVENTOR(S): Tuba, Zoltan; Bor, Maria

PATENT ASSIGNEE(S): Richter, Gedeon, Vegyeszeti Gyar Rt.

SOURCE: Ger. Offen., 19 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2130281	A	19720127	DE 1971-2130281	19710618
AT 314746	B	19740425	AT 1971-5022	19710609
ZA 7103785	A	19720126	ZA 1971-3785	19710611
FR 2109619	A5	19720526	FR 1971-22082	19710617
ES 392355	A1	19740801	ES 1971-392355	19710617
NL 7108384	A	19711221	NL 1971-8384	19710618
JP 48019636	B4	19730614	JP 1971-43849	19710618
PRIORITY APPLN. INFO.:			HU 1970-RI392	A 19700618

GI For diagram(s), see printed CA Issue.


AB 6,17-Seco-16, 17-imide derivs. I of steroids, useful as intermediates for bactericidal compds., were prepared from corresponding 16, 17-dioxo 16-oximes by treatment with AcOH and H₂SO₄ or from corresponding Me 16,

10/825,758




RN 37005-46-2 CAPLUS

CN 17-Aza-D-homoandrostande-3,16,17a-trione, (5α)- (9CI) (CA INDEX NAME)



RN 37005-49-5 CAPLUS

CN 17-Aza-D-homoandrostande-16,17a-dione, 3-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3β,5α)- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1972:113430 CAPLUS
DOCUMENT NUMBER: 76:113430
TITLE: Steroid D-homo-imide derivatives
INVENTOR(S): Tuba, Zoltan; Bor, Mrs. Dezso
PATENT ASSIGNEE(S): Richter, Gedeon, Vegyeszeti Gyar Rt.
SOURCE: Hung. Teljes, 14 pp.
CODEN: HUXXB
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

10/825,758

HU 3040

19711122 HU

19700618

GI For diagram(s), see printed CA Issue.

AB I in AcOH treated with aqueous H₂SO₄ at 60° and the mixture heated 1 hr at 85-95° in N gave 88% II. II was also prepared in 90% yield by treating III with NaOMe-MeOH. IV (Q = α -H, β -OH; α -H, β -OAc; OCH₂CH₂O) were prepared similarly.


IT 35570-05-9P 35570-06-0P 35574-26-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 35570-05-9 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4a,4b,5,6,10b,11,12,12a-octahydro-8-methoxy-12a-methyl-, (4aS,4bR,10bS,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 35570-06-0 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-hydroxy-10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35574-26-6 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 8-(acetyloxy)tetradecahydro-10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/825,758



L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1969:450320 CAPLUS

DOCUMENT NUMBER: 71:50320

TITLE: Studies in the steroid group. LXXIX. Preparation of 2-aza-3-oxo, 3-aza-2-oxo-, 16-aza-17-oxo-, and 17-aza-16-oxo-5 α -androstane, and of 3-aza-2-oxo-5 α -cholestane

AUTHOR(S): Jones, Ewart R. H.; Meakins, George D.; Tuba, K. Z.

CORPORATE SOURCE: Dyson Perrins Lab., Oxford

SOURCE: Journal of the Chemical Society [Section] C: Organic (1969), (11), 1597-602

CODEN: JSOOAX; ISSN: 0022-4952

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The title steroids were prepared by routes in which the yields at all stages are higher than 70%. For the ring-A lactams the key stages involve ring opening of 3-oxa- and 3-aza-2,4-diones; attack by nucleophiles occurs selectively at position 4. 17-Aza-5 α -androstane-16-one is readily obtained by Beckmann rearrangement of the 16-hydroxyimino-17-ketone to 17-aza-D-homo-5 α -androstane-16,17 α -dione, followed by Hofmann degradation. The 16-aza-17-oxo-isomer was prepared from the 17-ketone in six stages by a sequence similar to that used previously for other 16-aza steroids.

IT 17916-38-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17916-38-0 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4 α ,4 β ,5,6,6 α .alph
a.,7,8,9,10,10 α ,10 β ,11,12,12 α -tetradecahydro-10 α β ,12 α β -
dimethyl- (8CI) (CA INDEX NAME)



L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1969:450319 CAPLUS

DOCUMENT NUMBER: 71:50319

TITLE: Studies in the steroid group. LXXX. Proton magnetic

resonance and mass spectra of 2-aza-3-oxo-, 3-aza-2-oxo, 16-aza-17-oxo-, and 17-aza-16-oxo-5 α -androstande

AUTHOR(S): Aplin, Robin T.; Meakins, George D.; Tuba, K. Z.; Woodgate, P. D.

CORPORATE SOURCE: Dyson Perrins Lab., Oxford, UK

SOURCE: Journal of the Chemical Society [Section] C: Organic (1969), (11), 1602-4
CODEN: JSOOAX; ISSN: 0022-4952

DOCUMENT TYPE: Journal

LANGUAGE: English


GI For diagram(s), see printed CA Issue.

AB Spectrometric examination establishes the structures of the title steroids (I-IV). In the mass spectrum of one of the ring-D lactams (the 17-aza-16-oxo isomer) the base peak arises from the (M-15) ion, and no other peak has an abundance of more than 8%. Distinction between the ring-A lactams depends upon differentiation, by ¹H N.M.R., between the units >CHCH₂-CONHCH₂- and >CHCH₂NHCOCH₂-.

IT **17916-38-0**
RL: PRP (Properties)
(nuclear magnetic resonance of)

RN 17916-38-0 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4a α ,4b β ,5,6,6a.alpha.a.,7,8,9,10,10a,10b α ,11,12,12a-tetradecahydro-10a β ,12a β -dimethyl- (8CI) (CA INDEX NAME)



L4 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1968:87450 CAPLUS

DOCUMENT NUMBER: 68:87450

TITLE: Simple route to 17-aza-5 α -androstan-16-one

AUTHOR(S): Jones, Ewart R. H.; Meakins, George D.; Tuba, K. Z.; Woodgate, P. D.

CORPORATE SOURCE: Dyson Perrins Lab., Oxford, UK

SOURCE: Chemical Communications (London) (1968), (4), 210-11
CODEN: CCOMA8; ISSN: 0009-241X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 68:87450

GI For diagram(s), see printed CA Issue.


AB A 3-step preparation of the title compound (I) in 48% yield is described. In the preparation, 5 α -androstan-17-one is converted (tert-BuOK, RONO) to the 16-hydroxyimino derivative which is then subjected to a Beckmann rearrangement (H₂SO₄, AcOH, H₂O) to give II. II is converted (Br₂-NaOMe-MeOH) to I.

IT **17916-38-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17916-38-0 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 4a α ,4b β ,5,6,6a.alpha.a.,7,8,9,10,10a,10b α ,11,12,12a-tetradecahydro-10a β ,12a β -

dimethyl- (8CI) (CA INDEX NAME)



L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1963:455319 CAPLUS

DOCUMENT NUMBER: 59:55319

ORIGINAL REFERENCE NO.: 59:10153g-h,10154d-f

TITLE: A novel rearrangement of cyclic α -nitro ketones

AUTHOR(S): Hassner, Alfred; Larkin, John

CORPORATE SOURCE: Univ. of Colorado, Boulder

SOURCE: Journal of the American Chemical Society (1963), 85(14), 2181-2

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 59:55319

GI For diagram(s), see printed CA Issue.

AB cf. Larson and Wat, CA 58, 12603d. Steroidal α -nitro ketones are converted to N-hydroxy imides under acid conditions. From I, m. 105-7° (a 1:1 mixture of 16 α and 16 β epimers by nuclear magnetic resonance were prepared the following II (R, R', m.p., and % yield): H, H, 260-3°, 75; Ac, Ac (III), 231-2°, 80; Ac, H (IV), 241-5°, 75; H, Me, 214-15°, 95; Ac, Me, 186-8°, 85. The conversion of the 5,6-dihydro derivative, prepared from I in 95% yield (m. 180-2°), results in an analogous series: 5,6-dihydro derivative of III, m. 180-2°, 80%, of IV, m. 224-6°, 80%. IV is also obtained in 75% yield by the reaction of V with NH₂OH. Hydrolysis of III with KOH at room temperature gives II. With tert-BuOK, III is converted to 3 β -hydroxy-16,17-seco-5-androstene-16,17-dioic acid. N-Acetoxy-2,3-secocholestane-2,3-dioic acid amide, m. 205-7° (decomposition), was prepared in 75% yield from 2-nitrocholestanone (m. 135-6°) and Ac₂O, or upon treatment with HCl, followed by acetylation of the intermediate N-hydroxy imide, m. 184-8°. II is stable to acid hydrolysis even in the presence of levulinic acid. VI, m. 210-12°, was prepared by the LiAlH₄-AlCl₃ reduction of III followed by acetylation. The structure assignment of an N-hydroxyimide rather than an isomeric anhydride oxime is based on infrared spectra and chemical transformations. Two possible mechanisms are discussed.


IT 100627-30-3, Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-2,8-dihydroxy-10a,12a-dimethyl-, 8-acetate 102281-18-5, 16,17-Seco-5 α -androstane-16,17-dioic imide, N-3 β -dihydroxy-, 3-acetate 103308-17-4, Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 2-acetoxytetradecahydro-8-hydroxy-10a,12a-dimethyl-, acetate (preparation of)

RN 100627-30-3 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-2,8-dihydroxy-10a,12a-dimethyl-, 8-acetate (7CI) (CA INDEX NAME)

Absolute stereochemistry.


10/825,758



RN 102281-18-5 CAPLUS

CN 16,17-Seco-5α-androstane-16,17-dioic imide, N,3β-dihydroxy-,
3-acetate (7CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 103308-17-4 CAPLUS

CN 16,17-Seco-5α-androstane-16,17-dioic imide, N-acetoxy-3β-
hydroxy-, acetate (7CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1963:455317 CAPLUS

DOCUMENT NUMBER: 59:55317

ORIGINAL REFERENCE NO.: 59:10152h,10153a-d,10154a-d

TITLE: Yohimbine derivatives

INVENTOR(S): Albright, Jay D.; Goldman, Leon

PATENT ASSIGNEE(S): American Cyanamid Co.

SOURCE: 26 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 619567		19631231	BE	
FR 1335543			FR	
FR M2170			FR	
GB 1007827			GB	
PRIORITY APPLN. INFO.:			US	19620410


GI For diagram(s), see printed CA Issue.

AB Derivs. of yohimbine substituted at the 16, 17, and (or) 18 C atoms were hypotensive agents with low toxicity; some were tranquilizers as well. A cold mixture of 10 g. yohimban-17-one (I) 10 g. MeONa, and 300 cc. dry C₆H₆ was treated with 14 cc. HCO₂Et, stirred 20 h. at room temperature under N, and poured on 300 g. ice and 200 cc. H₂O; the organic layer was washed with 0.1N soda. Neutralization of the combined washings and aqueous layer with AcOH precipitated 9.4 g. 18-hydroxymethyleneyohimban-17-one (II) hemihydrate, m. 207-10° (MeOH) (decomposition, sintered to a glass 145-8°); the mother liquor gave an addnl. 1.8 g. product. In a similar manner, 5 g. I treated with 1 g. MeONa and 17 cc. (CO₂Et)₂ yielded 3.41 g. Et 17-oxoyohimban-18α-glyoxylate (III), m. 215-16° (decomposition). Reaction of 0.589 g. yohimban-16-one, 0.118 g. MeONa, and 2.0 cc. (CO₂Et)₂ in 40 cc. dry C₆H₆ 20 h., followed by addition of AcOH and ether, filtration, separation of Et₂O, and evaporation in vacuo of Et₂O yielded a residue, recrystd. to give 0.107 g. Et 16-oxoyohimban-17β-glyoxylate (IV), m. 192-5° (decomposition; bath preheated to 180°). Filtration, after 24 h, of a mixture of 0.22 g. alloyohimban-17-one, 0.444 g. MeONa, and 7.5 cc. (CO₂Et)₂ in 150 cc. C₆H₆ gave the Na salt of the enol form of the product. The salt, dissolved in MeOH and passed over a column of Amberlite IRC-50 (H⁺), was converted to Et 17-oxoalloyohimban-16β-glyoxylate, m. 207-9° (decomposition) [picrate, prepared from acidified Na salt, m. 198-201° (decomposition)]. A mixture of 1.0 g. II, 0.225 g. NH₂OH.HCl, and 15 cc. AcOH, heated 6 min. at 100°, chilled, and filtered, furnished a residue recrystd. from MeOH to 0.148 g. mixed yohimbano[17,18-c]isoxazole HCl.0.25H₂O and yohimbano[18,17-d]isoxazole-HCl.0.25H₂O, m. 310-15° (decomposition). Yohimbano[17,18-c]pyrazole (V) (4.61 g.), m. 240-4° (decomposition), was prepared by refluxing for 0.5 h. a mixture of 5.0 g. II, 0.80 cc. H₂NNH₂.H₂O, and 100 cc. EtOH, evaporation of solvent in vacuo the following day, and recrystn. of the residue from MeOH. Substitution of H₂NNH₂.2HCl gave yo-himbano[17,18-c]pyrazole-2HCl.0.25H₂O, m. 301-5°. A cold mixture of 1 g. V and 0.84 cc. Et₃N in 45 cc. dry CHCl₃ was treated with 0.79 g. 3,4,5-(MeO)₃C₆H₂COCl, let stand 18 h. at room temperature, washed with Na₂CO₃ solution and dried; removal of solvent in vacuo, trituration of the residue with absolute EtOH, and filtration gave 1.05 g. mixture of 5,8,8aβ,9,12,13,13aα,14,14a.α,15-deca-hydro-12-(3,4,5-trimethoxybenzoyl)- and 5,8,8aβ,9,11,13,13aα,-14,14aα,15 - decahydro - 11 - (3,4,5 - trimethoxybenzoyl) - 6H- in-dazolo[5,6-g]indolo[2,3-a]quinolizine, m. 234-6° (decomposition). Refluxing 5.0 g. II and 1.05 cc. PhNHNH₂ in 100 cc. EtOH for 30 min., filtering the following day, and removing the solvent gave a glass, recrystd. from EtOAc to yield 3.91 g. mixture of 5,8,8aβ,-9,11,13,13aα,14,14aα,15-decahydro-11-phenyl- and 5,8,8aβ,9,-12,13,13aα, 14,14aα, 15 - decahydro - 12 - Ph - 6H- indazolo [5,6-g]indolo[2,3-a]quinolizine, m. 195-212° (decomposition); fractional crystallization from MeOH, then EtOAc gave 1.15 g. isomer, m. 203-7° (decomposition) and 1.20 g. isomer, m. 248-55° (decomposition). A mixture of 0.60 g. IV, 0.08 cc. H₂NNH₂.H₂O, and 25 cc. EtOH, refluxed 30 min. and allowed to stand overnight, furnished 0.547 g. orange glass on removal of the solvent. Recrystn. from Et-OAc gave Et 4,5,5aα,6,8,9,14,14bβ,15,15aβ-decahydro-2H-in-dazolo[6,7-g]indolo[2,3-a]quinolizine-3-carboxylate-0.75H₂O, m.

277-83° (decomposition, sintered at 150°). In the same manner, reaction of 0.40 g. IV and 0.11 cc. PhNHNH₂, in 25 cc. EtOH yielded 0.58 g. glass, recrystd. from EtOH to give a mixture of Et 1,4,5,5a α ,8,9,14,14b β ,15,15a β -decahydro-1-phenyl-6H- and 4,5,-5a α ,6,8,9,14,14b β , 15,15a β - decahydro - 2 - Ph - 2H -indazolo-[6,7-g]indolo[2,3-a]quinolizine-3-carboxylate-0.5H₂O, m. 236-40° (decomposition). A mixture of 0.06 cc. H₂NNH₂.H₂O, 0.495 g. III, and 35 cc. absolute EtOH, refluxed 1.5 h and treated as above gave 0.46 g. residue, worked up using EtOH-CH₂Cl₂ and Et₂O for precipitation, gave Et 5,8,8a β ,9,11,13,13a α ,14,14a α ,15-decahydro-6H-indazolo[5,6-g]indolo[2,3-a]quinolizine-10-carboxylate, m. 289-93° (decomposition).

IT 103308-17-4, Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, 2-acetoxytetradecahydro-8-hydroxy-10a,12a-dimethyl-, acetate (preparation of)
 RN 103308-17-4 CAPLUS
 CN 16,17-Seco-5 α -androstane-16,17-dioic imide, N-acetoxy-3 β -hydroxy-, acetate (7CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1959:94954 CAPLUS
 DOCUMENT NUMBER: 53:94954
 ORIGINAL REFERENCE NO.: 53:17191c-i
 TITLE: Ring D steroid oximes and the Beckmann rearrangement
 AUTHOR(S): Heard, R. D. H.; Ryan, Michael T.; Bolker, H. I.
 CORPORATE SOURCE: McGill Univ., Montreal, Can.
 SOURCE: Journal of Organic Chemistry (1959), 24, 172-5
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 53:94954

AB Whereas simple ring D and ring A steroid oximes yielded the corresponding oxime acetates on subjection to mild acetylating conditions, 3 β -hydroxyandrostane-16,17-dione 16-oxime (I) gave a pure crystalline compound which was characterized by its chemical properties and behavior as an intermediate in a Beckmann rearrangement. Rearrangement could be completed under appropriate, though equally mild, conditions. Reasons for the unexpected rearrangement under such mild conditions are advanced. I purified by dissolving 2.95 g. crude product in 40 ml. MeOH and 10 ml. H₂O, refluxing with C, and concentrating gave 70% I, m. 220°, λ 240 m μ , ϵ 9570. I(100 mg.) in 1 ml. C₅H₅N and 1 ml. Ac₂O left overnight gave 102 mg. C₂₃H₃₃O₅N (II), m. 163-5° (Et₂O), λ 223 m μ , ϵ 9431, stable in the dark, turned yellow within 1 week when exposed to light, and unstable in alc. (223 m μ peak disappeared). The structure of II corresponded to that of an intermediate in the Beckmann rearrangement of I. Oximes were prepared in the usual way by refluxing in alc. for 2 hrs. in the presence of excess NH₂OH.HCl and


NaOAc. Acetylating conditions identical to those used in preparing II were used and the authenticity of the acetates was established by alkaline hydrolysis to the starting oximes. 17-Oximino-3 β -acetoxyandrostane, m. 184-6°, gave 17-acetoximino-3 β -acetoxyandrostane, m. 180-0.5°; cholestanone oxime, m. 200-1°, gave 3-acetoximincholestanone, m. 124-38°; testosterone oxime, m. 222-3°, gave 17 β -acetoxy-3-acetoximino-4-androstene. II (0.5 g.) in 50 ml. 95% alc. was refluxed and samples were drawn at 1 hr. intervals and after the appropriate dilution measured in the spectrophotometer at 223 m μ . The ϵ value change with time was as follows (time in hrs. and ϵ value given): 0, 9400; 1, 1410; 3, 427; 4, 427. After 6 hrs. an oil (III) was obtained; it was insol. in aqueous Na₂CO₃ and could not be extracted from an Et₂O solution with alkali. III (0.5 g.) in 50 ml. alc. refluxed 20 hrs. with 2.5 g. KOH gave a mixture of 3 β -hydroxy-16,17-secoandrostane-16,17-dioic imide (IV) and 3 β -hydroxy-16,17-seco-16,17-dioic acid 17-amide (V). CHCl₃ (60 ml.) added to the acidified aqueous suspension dissolved IV; the suspension filtered, and the precipitate collected and dried gave 220 mg. V, m. 218.5-20.5°. V dissolved in cold AcOH and treated with NaNO₂ gave no evolution of N, which confirmed the tertiary nature of the amide group. The CHCl₃ solution gave 113 mg. IV, m. 180-2.5° (MeOH-H₂O). IV refluxed 24 hrs. in 10% aqueous KOH gave V. V (40 mg.) heated gradually to 200° with 5 ml. 20% KOH in glycerol gave a copious evolution of N. The heating stopped after 2.5 hrs., the mixture diluted with H₂O, acidified, and left 2 hrs., and the solid filtered off and washed gave 20 mg. II.

IT 35570-06-0, 16,17-Seco-5 α -androstane-16,17-dioic imide,
3 β -hydroxy- 119013-51-3, 16,17-Seco-5 α -androstane-
16,17-dioic imide, 3 β -hydroxy-, diacetate
(preparation of)

RN 35570-06-0 CAPLUS

CN Naphth[2,1-f]isoquinoline-1,3(2H,4H)-dione, tetradecahydro-8-hydroxy-
10a,12a-dimethyl-, (4aS,4bR,6aS,8S,10aS,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 119013-51-3 CAPLUS

CN 16,17-Seco-5 α -androstane-16,17-dioic imide, 3 β -hydroxy-,
diacetate (6CI) (CA INDEX NAME)

Absolute stereochemistry.

10/825,758



=> d his

(FILE 'HOME' ENTERED AT 14:02:40 ON 27 JAN 2005)

FILE 'REGISTRY' ENTERED AT 14:03:00 ON 27 JAN 2005

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 87 S L1 FULL


FILE 'CAPLUS' ENTERED AT 14:03:43 ON 27 JAN 2005

L4 24 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Day : Thursday

Date: 1/27/2005

Time: 14:11:22

PALM INTRANET

Inventor Name Search Result

Your Search was:

Last Name = POTTER

First Name = BARRY

Application#	Patent#	Status	Date Filed	Title	Inventor Name 51
60513217	Not Issued	159	10/23/2003	COMPOUND	POTTER, BARRY V.L.
60436635	Not Issued	159	12/30/2002	COMPOUND	POTTER, BARRY VICTOR LLOYD
60365258	Not Issued	159	03/18/2002	REGULATION OF INS (3456)P4 SIGNALLING BY A REVERSIBLE KINASE/PHOSPHATASE AND METHODS AND COMPOSITIONS RELATED THERETO	POTTER, BARRY V.L.
60346483	Not Issued	159	01/07/2002	COMPOUND	POTTER, BARRY VICTOR LLOYD
60218730	Not Issued	159	07/17/2000	COMPOSITION	POTTER, BARRY VICTOR LLOYD
60139520	Not Issued	159	06/16/1999	USE	POTTER, BARRY V. L.
29164622	D474127	150	07/30/2002	LOCKET	POTTER, BARRY M
29147976	D464287	150	09/13/2001	LOCKET	POTTER, BARRY
10991137	Not Issued	019	11/17/2004	COMPOUND	POTTER, BARRY VICTOR LLOYD
10955962	Not	019	09/30/2004	STEROID 3-O-SULPHAMATE	POTTER,

	Issued			DERIVATIVES AS INHIBITORS OF OESTRONE SULPHATASE	BARRY VICTOR LLOYD
<u>10825758</u>	Not Issued	030	04/16/2004	STEROIDAL COMPOUNDS FOR INHIBITING STEROID SULPHATASE	POTTER, BARRY VICTOR LLOYD
<u>10730589</u>	Not Issued	030	12/08/2003	THERAPEUTICS	POTTER, BARRY V.L.
<u>10728383</u>	Not Issued	041	12/05/2003	COMPOSITIONS COMPRISING OESTRONE-3-O-SULPHAMATE AND TRAIL (TNF-RELATED APOPTOSIS INDUCING LIGAND)	POTTER, BARRY VICTOR LLOYD
<u>10690708</u>	Not Issued	030	10/23/2003	COMPOUND	POTTER, BARRY VICTOR LLOYD
<u>10674892</u>	Not Issued	030	09/30/2003	COMPOUND	POTTER, BARRY VICTOR LLOYD
<u>10469954</u>	Not Issued	030	03/17/2004	USE	POTTER, BARRY VICTOR LLOYD
<u>10367623</u>	Not Issued	030	02/14/2003	THIOETHER SULPHAMATE STEROIDS AS STEROID INHIBITORS AND ANTI-CANCER COMPOUNDS	POTTER, BARRY VICTOR LLOYD
<u>10367622</u>	Not Issued	030	02/14/2003	17-ARYL LINKER DERIVATISED ESTROGEN 3-SULPHAMATES AS INHIBITORS OF STEROID SULPHATASE	POTTER, BARRY VICTOR LLOYD
<u>10367114</u>	Not Issued	083	02/14/2003	OESTROGEN-17-SULPHAMATES AS INHIBITORS OF STEROID SULPHATASE	POTTER, BARRY VICTOR LLOYD
<u>10343667</u>	Not Issued	019	01/01/0001	NAADP ANALOGUES FOR MODULATING T-CELL ACTIVITY	POTTER, BARRY V L
<u>10327500</u>	Not Issued	041	12/20/2002	COMPOUND	POTTER, BARRY VICTOR LLOYD
<u>10300494</u>	Not	041	11/20/2002	COMPOUND	POTTER,

	Issued				BARRY VICTOR LLOYD
<u>10120275</u>	Not Issued	041	04/10/2002	COMPOSITION	POTTER, BARRY VICTOR LLOYD
<u>10084235</u>	Not Issued	061	02/25/2002	STEROID SULPHATASE INHIBITORS	POTTER, BARRY VICTOR
<u>10082007</u>	<u>6677325</u>	150	02/21/2002	STEROID SULPHATASE INHIBITORS	POTTER, BARRY VICTOR LLOYD
<u>10013798</u>	Not Issued	061	12/10/2001	USE	POTTER, BARRY VICTOR LLOYD
<u>09868348</u>	Not Issued	161	06/15/2001	CYCLIC ADENOSINE DIPHOSPHATE RIBOSE ANALOGUES FOR MODULATING T CELL ACTIVITY	POTTER, BARRY V L
<u>09794853</u>	Not Issued	094	02/27/2001	STEROID SULPHATASE INHIBITORS	POTTER, BARRY VICTOR LLOYD
<u>09755429</u>	<u>6653298</u>	150	01/05/2001	COMPOSITION	POTTER, BARRY VICTOR LLOYD
<u>09724986</u>	<u>6676934</u>	150	11/28/2000	PHARMACEUTICAL COMPOSITION WITH TUMOR NECROSIS FACTOR A AND 2-METHOXYESTRONE-3-0-SULPHAMATE FOR INHIBITION OF ESTRONE SULPHATASE	POTTER, BARRY VICTOR LLOYD
<u>09638315</u>	<u>6506792</u>	150	08/14/2000	COMPOUNDS THAT INHIBIT OESTRONE SULPHATASE AND/OR AROMATASE AND METHODS FOR MAKING AND USING	POTTER, BARRY VICTOR LLOYD
<u>09638314</u>	Not Issued	094	08/14/2000	COMPOUND	POTTER, BARRY VICTOR LLOYD
<u>09579163</u>	<u>6642397</u>	150	05/25/2000	STEROID SULPHATASE INHIBITORS	POTTER, BARRY VICTOR LLOYD

<u>09572246</u>	Not Issued	094	05/17/2000	STEROID 3-O-SULPHAMATE DERIVATIVES AS INHIBITORS OF OESTRONE SULPHATASE	POTTER, BARRY VICTOR LLOYD
<u>09572237</u>	6670353	150	05/17/2000	OXIME-GROUP CONTAINING OESTRONE SULPHATASE INHIBITORS	POTTER, BARRY VICTOR LLOYD
<u>09561453</u>	Not Issued	093	04/28/2000	METHODS FOR TREATING OR PREVENTING CANCER BY PREVENTING, INHIBITING OR ARRESTING CELL CYCLING	POTTER, BARRY VICTOR LLOYD
<u>09319213</u>	6642220	150	11/23/1999	COMPOUND	POTTER , BARRY VICTOR LLOYD
<u>09238345</u>	6187766	150	01/27/1999	STEROID SULPHATASE INHIBITORS	POTTER , BARRY VICTOR
<u>09193970</u>	6476011	150	11/18/1998	METHODS FOR INTRODUCING AN ESTROGENIC COMPOUND	POTTER , BARRY VICTOR LLOYD
<u>09193969</u>	6159960	150	11/18/1998	STEROID SULPHATASE INHIBITORS.	POTTER , BARRY VICTOR LLOYD
<u>09142194</u>	6083978	150	09/02/1998	COMPOUNDS WITH A SULFAMATE GROUP	POTTER , BARRY V
<u>09125255</u>	6239169	150	08/14/1998	NON-STEROIDAL POLYCYCLIC RING SULPHAMATE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS OESTRONE SULPHATASE INHIBITORS	POTTER , BARRY V.
<u>09111927</u>	6011024	150	07/08/1998	STEROID SULPHATASE INHIBITORS	POTTER , BARRY VICTOR LLOYD
<u>09044984</u>	6017904	150	03/20/1998	STEROID SULPHATASE INHIBITORS	POTTER , BARRY VICTOR LLOYD
<u>08458352</u>	5830886	150	06/02/1995	STEROID SULPHATASE INHIBITORS	POTTER , BARRY V L
<u>08456122</u>	5861390	150	05/31/1995	STEROID SULPHATASE INHIBITORS	POTTER

					, BARRY V.
<u>08196192</u>	<u>5616574</u>	150	12/27/1994	STEROID SULPHATASE INHIBITORS	POTTER, BARRY V. L.
<u>08196191</u>	<u>5604215</u>	150	12/27/1994	STEROID SULPHATASE INHIBITORS	POTTER, BARRY V. L.
<u>08141700</u>	Not Issued	168	10/26/1993	INOSITOL PHOSPHATE ANALOGUES	POTTER, BARRY VICTOR L.
<u>07401448</u>	Not Issued	166	11/07/1989	INOSITOL PHOSHATE ANALOGUES	POTTER, BARRY VICTOR L.
<u>07232287</u>	<u>4890601</u>	150	08/15/1988	GAS BURNER	POTTER, BARRY C.

[Search and Display More Records.](#)

	Last Name	First Name
Search Another:	<input type="text" value="Potter"/>	<input type="text" value="Barry"/>
Inventor	<input type="button" value="Search"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)